Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

SPRYCEL(R) (Dasatinib) Shows Potential As Treatment For Prostate Cancer
Bristol-Myers Squibb Company (NYSE: BMY) announced interim results from two Phase II studies of SPRYCEL® (dasatinib) which demonstrate that the medicine may have potential as a treatment for a certain type of advanced prostate cancer.

Long-Suffering Rohingya In Bangladesh Face Unacceptable Abuse
Thousands of unregistered Rohingya refugees living in the Kutupalong makeshift camp, Bangladesh, are being forcibly displaced from their homes, in an act of intimidation and abuse by the local authorities. The international medical organization Doctors Without Border/Mç©decins Sans Frontiç¨res (MSF) has treated numerous people for injuries, of which the majority were women and children. Furthermore, MSF has witnessed countless destroyed homes and heard many reports of people being warned to remove their own shelters or face the consequences.
News of the day
Food Additive May One Day Help Control Blood Lipids And Reduce Disease Risk
Scientists at Washington University School of Medicine in St. Louis have identified a substance in the liver that helps process fat and glucose. That substance is a component of the common food additive lecithin, and researchers speculate it may one day be possible to use lecithin products to control blood lipids and reduce risk for diabetes, hypertension or cardiovascular disease using treatments delivered in food rather than medication.
Medical Devices

Prostate Cancer Patients Disease Free After Five Years Likely To Be Disease Free After 10 Years

Prostate cancer patients who receive brachytherapy and remain free of disease for five years or greater are unlikely to have a recurrence at 10 years, according to a study in the July 1 issue of the International Journal of Radiation Oncology Biology Physics, the official journal of the American Society for Radiation Oncology (ASTRO). Brachytherapy is the placement of radioactive s in or just next to a tumor either permanently or temporarily, depending upon the cancer. In the study, researchers at The Mount Sinai Medical Center Departments of Radiation Oncology and Urology in New York followed 742 prostate cancer patients who were treated with brachytherapy alone, brachytherapy and hormonal therapy, or combined brachytherapy and external beam radiotherapy (EBRT) between 1991 and 2002. None of these patients had recurred during their first five years post-treatment. They found that the PSA level taken at five years was an indicator of how well a patient would do in the future and the overall chance of being cancer free at 10 years was 97 percent. Also, none of the study participants developed metastatic disease or died from prostate cancer. "Our data have indicated that improvements in treatment are continuing and that these will continue to have an effect on prostate brachytherapy data for years to come," Richard Stock, M.D., lead author of the study and chairman of radiation oncology at The Mount Sinai Medical Center, said. "Late failure rates will continue to decrease, making prostate brachytherapy alone and combined with hormonal therapy and/or EBRT an increasingly attractive treatment option." ASTRO is the largest radiation oncology society in the world, with more than 10,000 members who specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, biology and physics, the Society is dedicated to improving patient care through education, clinical practice, advancement of science and advocacy. American Society for Radiation Oncology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009